SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 21, 2001
BIOTRANSPLANT INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE 000-28324 04-3119555
------------------------------- ------------------------- ----------------
(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation) Identification No.)
Building 75, Third Avenue
Charlestown Navy Yard
Charlestown, MA 02129
------------------------------------- -----------------
(Address of principal executive (Zip Code)
offices)
Registrant's telephone number, including area code: (617) 241-5200
N/A
-------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events.
On February 21, 2001, Dr. Elliot Lebowitz, President and Chief Executive
Officer of BioTransplant Incorporated, made a slide presentation at the
BIO-CEO and Investor Conference relating to BioTransplant's business and its
proposed merger with Eligix, Inc. and BioTransplant webcast the presentation.
See the transcript of the webcast attached hereto as Exhibit 99.1.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
See Exhibit Index attached hereto.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: February 21, 2001 BIOTRANSPLANT INCORPORATED
By: /s/ Richard V. Capasso
----------------------------------
Richard V. Capasso
Vice President, Finance and Treasurer
3
EXHIBIT INDEX
EXHIBIT NO. EXHIBIT
Exhibit 99.1 Transcript of the Company's webcast held
on February 21, 2001
4